Avecia Biologics is a leader in the process development and manufacture of biologics, offering proprietary expression and gene manipulation systems for microbial- and mammalian-derived biopharmaceuticals. This includes its pAVEway™ advanced protein expression technology for fast-track process creation and development. Based in the Tees Valley in the north-east of the UK, the company has a proven track record in the development of innovative bioprocesses for over 30 years. It operates one of Europe's largest cGMP contract manufacturing facilities for recombinant protein biologics, offering flexible capacity from 100L - 5000L for all stages of the product pipeline. A strong project-team focus ensures close customer collaboration at all stages of the customer programme and has supported the development of over 40 recombinant proteins for many clients in Europe, USA and Japan.